Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.999.309 €): MyPal: Förderung der Palliativversorgung von Erwachsenen und krebskranken Kindern durch fortgeschrittene Patienten-Berichtssysteme Hor01.01.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
MyPal: Förderung der Palliativversorgung von Erwachsenen und krebskranken Kindern durch fortgeschrittene Patienten-Berichtssysteme
MyPal aims to foster early palliative care for cancer patients by leveraging patient reported outcome (PRO) systems through their adaptation to the personal needs of the cancer patient and his/her caregiver(s). Through this intervention, MyPal aspires to empower cancer patients (and their family members) in capturing more accurately their conditions, communicate them with a seamless and effective way to their healthcare providers and, ultimately, foster the time for action through the rapid identification of important deviations in the patient’s state and QoL. Providing this information in a timely and comprehensive manner throughout the disease course will reinforce the potential for applying a patient-centred and integrated palliative care approach for cancer with the participation of all relevant healthcare providers (i.e. oncologists, specialized physicians, psychologists, nurses), which is necessary to cope with the specific disease. In order to accomplish its mission, MyPal will exploit technological advances on digital health to support patients, family members and healthcare providers in gaining value through this systematic and comprehensive PRO-based intervention. Overall, the foreseen advancement through MyPal reflects a paradigm shift from passive patient reporting based on conventional PRO approaches to active patient engagement and a closed-loop approach (bridging the gap between patient reporting and effective actions by healthcare providers to meet the varying patient needs) for coping with palliative care challenges in cancer. MyPal will demonstrate and validate the proposed intervention in two clinical studies, an RCT for adults with hematologic cancers and an observational study for children suffering from solid tumors and hematologic malignancies, hence targeting different age groups and cancer types. The clinical studies will be conducted in diverse healthcare settings in 6 clinical sites from 5 European countries.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Atlantis Health UK Ltd. | 205.055 € |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | 556.941 € |
| European Association for Palliative Care | 96.250 € |
| Fakultni Nemocnice Brno | 160.000 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 467.500 € |
| Geniko Nosokomeio Thessalonikis G.Papanikolaou | 0,00 € |
| Idryma Technologias Kai Erevnas | 331.000 € |
| International Children's Palliative Care Network | 86.875 € |
| Karolinska Institutet | 206.875 € |
| Masarykova Univerzita | 86.250 € |
| Medizinische Hochschule Hannover | 282.140 € |
| Panepistimiako Geniko Nosokomeio Irakleiou | 159.000 € |
| Panepistimio Dytikis Attikis | 150.400 € |
| Promotion Software GmbH | 389.750 € |
| Universitat DES Saarlandes | 316.195 € |
| Universita Vita-Salute SAN Raffaele | 211.147 € |
| University of Lancaster | 293.931 € |
Quelle: https://cordis.europa.eu/project/id/825872
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.